Search filters

Filters
Clear All

Phase

  • 4
  • 11
  • 10
  • 14
  • 3
  • 60
  • 103
  • 17
  • 2
  • 103
  • 104
  • 1

Found 105 medicine trials

A listing of medicine medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Identification of neoantigen-specific T cell responses in cancer patients within the Penn Medicine BioBank
18 years - 90 years
All genders
You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.
 Fusion - FPX-01-01
18 years - 99 years
All genders
Phase 1
A first-in-man Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547. Includes a sub-study of FPI-1175 …
 Bupivacaine RCT- Bupivacaine as Adjuvant for Post-operative Pain in Mohs micrographic surgery
18 years - 99 years
All genders
The research study is being conducted to find the best ways to reduce pain after Mohs surgery. The research team hopes to learn if adding additional numbing medication at the end of surgery will help reduce pain afterwards. Penn Medicine patients having Mohs surgery will be invited to participate in …
 TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
18 years - 99 years
All genders
Phase 4
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine …
 TRILOGY
18 years - 65 years
All genders
The target population are patients at Penn Medicine undergoing elective bariatric surgery; and are additionally participating in POW-R study ( Protocol #843280) Patients will be recruited to undergo liver wedge and visceral adipose tissue biopsy and provide blood samples. Liver samples will be processed for RNA, metabolomics, and biochemical and …
 JAGUAR- ObJective Analysis to GaUge EVAR Outcomes Through Randomization
21 years - 99 years
All genders
Phase 4
This post-approval study will collect safety, performance, effectiveness, and neck dilatation data on Alto Abdominal Stent Graft System for the endovascular treatment of infrarenal abdominal aortic aneurysms and evaluate real-world outcomes in comparison to commercially available comparator devices. Penn Medicine patients with the Alto Abdominal Stent Graft System, a device …
 HOPE Trial
18 years - 99 years
All genders
HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid use, and that buprenorphine …
 Physiologic Response to Non-Invasive Respiratory Support in Obese Patients with Acute Hypoxemic Respiratory Failure from COVID-19
18 years - 99 years
All genders
This research study only enrolls hospitalized patients at Penn Medicine. The purpose of the study is to assess differences in respiratory and ventilation parameters between HFNC and helmet CPAP in obese patients with COVID-19 AHRF. We will enroll patients admitted to a HUP ICU with COVID-19 who have an obese …
18 years - 99 years
All genders
The purpose of the study is to find out whether an extra dose of COVID-19 study dose of vaccine will help to protect people who have had a liver or kidney transplant from COVID-19 by causing their body to make antibodies against the virus that causes COVID-19. Many transplant recipients …
 CHARM- Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction
18 years - 99 years
All genders
Phase 3
Interventional
This is a Phase 3 study, which means that BIIB093 (study drug) has already been investigated in previous clinical research studies with a small number of people with large hemispheric infarction (LHI). These studies suggested that the study drug was safe, did not cause serious side effects or discomfort, and …
61 - 70 of 105